Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press21110.17650/2222-1468-2016-6-2-65-69CLINICAL CASEКЛИНИЧЕСКИЙ СЛУЧАЙClinical experience in using lenvatinib in patients with progressive, radioactive iodine-refractory differentiated thyroid cancerКлинический опыт применения препарата ленватиниб у пациентов с прогрессирующим дифференцированным раком щитовидной железы, рефрактерным к терапии радиоактивным йодомIsaevP. A.ИсаевП. А.
Russian Federation

4 Koroleva St., Obninsk, Kaluga Region, 249036

249036, Калужская область, Обнинск, ул. Королева, 4

isaev@mrrc.obninsk.ruSeminD. Yu.СеминД. Ю.
Russian Federation

4 Koroleva St., Obninsk, Kaluga Region, 249036

249036, Калужская область, Обнинск, ул. Королева, 4

RumyantsevP. O.РумянцевП. О.
Russian Federation

1 Moskvorech’e St., Moscow, 115478,

115478, Москва, ул. Москворечье, 1

Il’inA. A.ИльинА. А.
Russian Federation

4 Koroleva St., Obninsk, Kaluga Region, 249036

249036, Калужская область, Обнинск, ул. Королева, 4

Pol’kinV. V.ПолькинВ. В.
Russian Federation

4 Koroleva St., Obninsk, Kaluga Region, 249036

249036, Калужская область, Обнинск, ул. Королева, 4

AgababyanT. A.АгабабянТ. А.
Russian Federation

4 Koroleva St., Obninsk, Kaluga Region, 249036

249036, Калужская область, Обнинск, ул. Королева, 4

Vasil’kovS. V.ВасильковС. В.
Russian Federation

4 Koroleva St., Obninsk, Kaluga Region, 249036

249036, Калужская область, Обнинск, ул. Королева, 4

MedvedevV. S.МедведевВ. С.
Russian Federation

4 Koroleva St., Obninsk, Kaluga Region, 249036

249036, Калужская область, Обнинск, ул. Королева, 4

ZhelonkinaN. V.ЖелонкинаН. В.
Russian Federation

4 Koroleva St., Obninsk, Kaluga Region, 249036

249036, Калужская область, Обнинск, ул. Королева, 4

A.F. Tsyb Medical Radiology Research Center – Branch of National Medical Radiology Research Center at the Ministry of Health of RussiaМедицинский радиологический научный центр им. А.Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава РоссииEndocrinology Research Center at the Ministry of Health of RussiaФГБУ «Эндокринологический научный центр» Минздрава России230620166265692306201623062016Copyright ©; 2016, Isaev P.A., Semin D.Y., Rumyantsev P.O., Il’in A.A., Pol’kin V.V., Agababyan T.A., Vasil’kov S.V., Medvedev V.S., Zhelonkina N.V.Copyright ©; 2016, Исаев П.А., Семин Д.Ю., Румянцев П.О., Ильин А.А., Полькин В.В., Агабабян Т.А., Васильков С.В., Медведев В.С., Желонкина Н.В.2016Isaev P.A., Semin D.Y., Rumyantsev P.O., Il’in A.A., Pol’kin V.V., Agababyan T.A., Vasil’kov S.V., Medvedev V.S., Zhelonkina N.V.Исаев П.А., Семин Д.Ю., Румянцев П.О., Ильин А.А., Полькин В.В., Агабабян Т.А., Васильков С.В., Медведев В.С., Желонкина Н.В.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/211

None of the variants of therapy currently available for patients with differentiated thyroid cancer (DTС) refracted to therapy with radioactive iodine 131I (RAI) is not radical and does not allow to obtain full complete recovery including this is related to traditional chemotherapy regimens increasing toxicity of treatment contribute to improvement of the clinical effect. With the introduction of multicinase inhibitors into clinical practice made it possible to increase improve therapeutic outcomes. In December of 2015 in the Russian Federation was registered lenvantinib for therapy of patients with progressing DTC resistant to RAI therapy, which according to opinion may substantially improve the results of treatment of such patients and has a potential to change current clinical practice. The article deals with description of 5 clinical cases of inoperable patients with DTС refractory to RAI therapy receiving treatment with lenvatinib in the frameworks of the international randomized clinical trial phase III SELECT. The range of therapeutic effects varied from complete regression of the tumour to stabilization.

differentiated thyroid cancerrefractory to therapy with radioactive iodineSELECTlenvatinibдифференцированный рак щитовидной железырефрактерный к терапии радиоактивным йодомисследование SELECTленватинибкомпания Эйсай1. O’Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010;15(2):146–56.O’Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010;15(2):146–56.2. Isaacs J.D., McMullen T.P., Sudhu S.B. et al. Predictive value of the Delphian and level VI nodes in papillary thyroid cancer. ANZ J Surg 2010;80(11):834–8.Isaacs J.D., McMullen T.P., Sudhu S.B. et al. Predictive value of the Delphian and level VI nodes in papillary thyroid cancer. ANZ J Surg 2010;80(11):834–8.3. Shimaoka K., Schoenfeld D.A., DeWys W.D. et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56(9):2155–60.Shimaoka K., Schoenfeld D.A., DeWys W.D. et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56(9):2155–60.4. Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940): 319–28.Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940): 319–28.5. Carr L.L., Mankoff D.A., Goulart B.H. et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16(21):5260–8.Carr L.L., Mankoff D.A., Goulart B.H. et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16(21):5260–8.6. Bible K.C., Suman V.J., Molina J.R. et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11(10):962–72.Bible K.C., Suman V.J., Molina J.R. et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11(10):962–72.7. Locati L.D., Licitra L., Agate L. et al. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer 2014;120(17):2694–703.Locati L.D., Licitra L., Agate L. et al. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer 2014;120(17):2694–703.8. Hoftijzer H., Heemstra K.A., Morreau H. et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161(6):923–31.Hoftijzer H., Heemstra K.A., Morreau H. et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161(6):923–31.9. Leboulleux S., Bastholt L., Krause T. et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13(9):897–905.Leboulleux S., Bastholt L., Krause T. et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13(9):897–905.10. Инструкция по применению лекарственного препарата для медицинского применения Ленвима. Доступно по ссылке: http://www.rlsnet.ru/tn_index_id_87756.htm. [Instructions for use of medicinal product for medical use Lenvima. Available at: http://www.rlsnet.ru/tn_index_id_87756.htm. (In Russ.)].Инструкция по применению лекарственного препарата для медицинского применения Ленвима. Доступно по ссылке: http://www.rlsnet.ru/tn_index_id_87756.htm. [Instructions for use of medicinal product for medical use Lenvima. Available at: http://www.rlsnet.ru/tn_index_id_87756.htm. (In Russ.)].11. Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30.Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30.